Winner Medical(SZ:300888) Sou Hu Cai Jing·2026-01-09 12:58Core Viewpoint - The company, Steady Medical (300888), has shown significant growth in its financial performance for the first three quarters of 2025, with a notable increase in both revenue and net profit compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue reached 7.897 billion yuan, representing a year-on-year increase of 30.1% [2]. - The net profit attributable to shareholders was 732 million yuan, up 32.36% year-on-year [2]. - The non-recurring net profit was 679 million yuan, reflecting a 43.93% increase year-on-year [2]. - In Q3 2025 alone, the company reported a single-quarter main revenue of 2.601 billion yuan, which is a 27.71% increase year-on-year [2]. - The single-quarter net profit attributable to shareholders was 240 million yuan, marking a 42.11% year-on-year increase [2]. - The non-recurring single-quarter net profit was 218 million yuan, showing a 50.77% increase year-on-year [2]. - The company's debt ratio stands at 33.87%, with investment income of 33.23 million yuan and financial expenses of -2.036 million yuan [2]. - The gross profit margin is reported at 48.32% [2]. Market Activity - As of January 9, 2026, the stock price closed at 39.17 yuan, with an increase of 1.03% [1]. - The trading volume was 42,600 hands, with a total transaction amount of 166 million yuan [1]. - The net outflow of main funds was 2.6842 million yuan, accounting for 1.62% of the total transaction amount [1]. - The net outflow of speculative funds was 6.6 million yuan, representing 3.98% of the total transaction amount [1]. - Retail investors saw a net inflow of 9.2841 million yuan, which is 5.59% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 22 institutions have provided ratings for the stock, with 18 giving a "buy" rating and 4 an "accumulate" rating [2]. - The average target price set by institutions over the past 90 days is 5.488 billion yuan [2].